San Diego-based biotechnology company, Cardiff Oncology, announced today that its management team will be actively involved in a fireside chat and one-on-one investor meetings at the 35th Annual Piper Sandler Healthcare Conference. The event, which will take place from November 28 to November 30, 2023, at the prestigious Lotte New York Palace in New York City, promises to be a pivotal moment for the company.
The fireside chat will showcase a thought-provoking presentation by Cardiff Oncology’s CEO, Mark Erlander. Set for November 29, 2023, from 10:00 to 10:25 AM ET, the session will delve into the company’s innovative approach to leveraging PLK1 inhibition as a strategy to develop novel cancer therapies.
To make this event accessible to all interested parties, Cardiff Oncology has made provisions for a live webcast. By visiting the “Events” section of their official website, individuals can register and tune in to the webcast as it unfolds. Furthermore, those unable to attend the live session can access the webcast replay once the presentation concludes.
Cardiff Oncology is acclaimed for its clinical-stage research and development of groundbreaking treatments for various cancer types. Their primary focus centers around onvansertib, an advanced PLK1 inhibitor that shows tremendous promise in combination with standard-of-care therapeutics across multiple clinical programs. This includes addressing metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer. Cardiff Oncology’s pioneering efforts aim to not only overcome treatment resistance but also provide superior clinical benefits compared to existing standard-of-care treatments.
For further information about the groundbreaking work of Cardiff Oncology, please visit their website at .
FAQs
1. What is PLK1 inhibition?
PLK1 inhibition refers to the use of drugs or therapies that target and inhibit the activity of polo-like kinase 1 (PLK1), an enzyme that plays a crucial role in regulating various cellular processes, including cell division and proliferation. By inhibiting PLK1, researchers hope to disrupt cancer cell growth and increase the effectiveness of cancer treatments.
2. What is onvansertib?
Onvansertib is an investigational drug developed by Cardiff Oncology that belongs to the class of PLK1 inhibitors. It is currently being evaluated in combination with standard-of-care therapeutics in clinical programs targeting different cancer types, including metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer.
3. How does Cardiff Oncology aim to provide superior clinical benefit?
Cardiff Oncology’s approach to delivering superior clinical benefits involves targeting tumor vulnerabilities and overcoming treatment resistance. By utilizing PLK1 inhibition in combination with standard-of-care therapies, the company aims to enhance the outcomes of cancer treatments and improve patients’ overall well-being.